Past exam of the biochemistry course of the University of Cambridge / 2025 / Paper 3 / Section II

A common transition into anaphase both releases chromosomes for separation and permits the spindle to organise cytokinesis; later safeguards delay final separation when segregation remains incomplete. Temporal coordination makes the events occur in the right order, while spatial coordination positions division between the separating chromosome sets. The two forms of control interact but are experimentally distinguishable.

S phase establishes sister chromatids and their association through cohesin. During mitosis, chromosome condensation and DNA topoisomerase II activity help prepare the copies for separation. Each sister's kinetochore should attach to the opposite spindle pole, producing biorientation. Aurora B contributes to error correction by destabilising inappropriate attachments. Attachment and tension affect this process, but the spindle checkpoint should not be described simply as a direct meter of equal tension on every chromosome.

Unattached kinetochores catalyse formation of the mitotic checkpoint complex, involving Mad2, BubR1, Bub3 and Cdc20. This inhibits productive anaphase-promoting complex activity toward key substrates. In a classic causal experiment, destruction of the last unattached kinetochore allowed anaphase to proceed, with chromosome-arm damage providing an important control. It was the inhibitory signalling structure, rather than the physical presence of one unaligned chromosome somewhere in the biological cell, that maintained the delay.^[ref]

Once attachment-associated checkpoint signalling is silenced and inhibitory complexes are dismantled, anaphase-promoting complex with Cdc20 promotes ubiquitin-dependent destruction of securin and mitotic cyclin B. securin destruction permits separase activity, which cleaves the remaining cohesion-bearing kleisin subunit. Non-cleavable Scc1 blocked sister separation in budding yeast, directly linking regulated proteolysis to the loss of chromosome cohesion.^[ref] Chromosome movement can then proceed through shortening of kinetochore-associated microtubules and separation of the spindle poles.

Destruction of cyclin B also lowers CDK1 activity. This changes the phosphorylation balance, allowing protein phosphatases to reverse mitotic modifications and permitting chromosome decondensation, nuclear reassembly and cytokinetic organisation. Thus regulated proteolysis produces two coordinated outputs: removal of a physical chromosome linkage and removal of the mitotic kinase state. Their sharing of a controller improves ordering, but it does not mean that cytokinesis physically waits for a sensor to count every chromosome at its destination.

For animal cytokinesis, overlapping microtubules of the central spindle and signals associated with astral microtubules specify an equatorial cortical region. centralspindlin recruits and regulates the guanine-nucleotide exchange factor ECT2, which promotes local RhoA activation. RhoA stimulates actin assembly and myosin II activity, organising the actomyosin ring that drives furrow ingression. This geometry aligns the division plane between the segregating chromosome masses. Spindle position can itself be set by cortical cell polarity cues, explaining how the same machinery supports either approximately symmetric or asymmetric division.

Depletion and localisation experiments distinguish the biochemical signal from a simple structural scaffold. Experiments in human biological cells showed that ECT2 is required for cortical RhoA and furrow assembly, and that different centralspindlin subunits have distinguishable consequences for these events. Loss of central-spindle localisation need not abolish every equatorial signal, because additional spatial inputs can persist.^[ref] Accordingly, central-spindle disruption should be assessed alongside astral signals, spindle orientation and direct measurements of the cortical activity zone.

Furrow ingression leaves an intercellular bridge with a midbody. Final abscission involves ESCRT-III-dependent membrane-remodelling machinery and must be distinguished from the earlier contractile event. Chromatin trapped in the bridge can sustain Aurora B-dependent signalling and delay abscission. Human-cell experiments connected persistent chromosome bridges with continued kinase activity and delayed final separation, reducing the risk of unsuccessful division and furrow regression.^[ref] This safeguard can provide time to resolve a problem; persistent bridges can still lead to breakage, regression or abnormal descendants.

A decisive experimental series would image labelled chromosomes, microtubules, cyclin B, active RhoA and the biological cell boundary in the same biological cells. Acute checkpoint inhibition predicts premature anaphase and increased segregation errors. Stabilised securin or cleavage-resistant cohesion should obstruct separation; persistent cyclin B should obstruct normal mitotic exit. Acute ECT2 loss can impair cytokinesis even when chromosome segregation proceeds, demonstrating separable downstream machinery. Use timed interventions after spindle assembly, independent depletion reagents, appropriately expressed rescue constructs and controls for global biological cell damage. Count chromosome allocation, furrow initiation, ingression and abscission separately; a binucleate endpoint does not reveal which step failed.

The checkpoint also has blind spots. A merotelic attachment, where one kinetochore binds microtubules from both poles, may evade an unattached-kinetochore signal and generate a lagging chromosome. Coordination is therefore layered rather than absolute: attachment surveillance, a shared proteolytic transition, spindle-directed cortical signalling and a late abscission checkpoint jointly reduce the chance of partitioning the genome incorrectly. The detailed geometry differs in organisms that divide with a cell plate or other cytokinetic mechanisms.

Bacterial and eukaryotic replication obey the same chemical constraints but use different replication machines, initiation controls and chromosome-management strategies. Both perform semiconservative replication, extend new DNA in the $5^{\prime }\to 3^{\prime }$ direction from a paired $3^{\prime }$ end, and therefore require repeated initiation on the lagging template. A useful comparison uses Escherichia coli and nuclear replication in a conventional eukaryote, while recognising that neither represents every organism in its group.

At an E. coli origin of replication, DnaA helps open oriC and promotes assembly of the initiation machinery. The DnaB DNA helicase is loaded with the assistance of loading factors, and two replication forks move away from the origin. Initiation responds to growth and the nucleotide-bound state of DnaA, with additional controls limiting immediate reinitiation. A bacterial chromosome need not always be single and circular: some bacteria have several replicons or linear chromosomes. Fast-growing bacteria can also begin a new round before the preceding round has finished, so replication and biological cell division do not have a universal one-round-to-one-division temporal relationship.

Nuclear eukaryotic chromosomes generally use many origin of replication sites. In G1 phase, the origin recognition complex, Cdc6 and Cdt1 load MCM2-7 around double-stranded DNA. This is replication origin licensing, not yet active replication fork movement. During S phase, cyclin-dependent kinases and Dbf4-dependent kinase promote assembly of the active CMG helicase, containing Cdc45, MCM2-7 and GINS. Elevated kinase activity also suppresses new licensing, separating origin competence from origin firing.

Purified budding-yeast reconstitution demonstrated these opposing kinase functions: cyclin-dependent kinase could inhibit DNA helicase loading while promoting assembly of active replication machinery after licensing, and Dbf4-dependent kinase supplied another required input. Ordered addition, component omission and kinase-dependence experiments establish biochemical requirements more directly than colocalisation in an S phase cell nucleus.^[ref] This protects a multi-origin genome against DNA rereplication. Not every licensed origin fires: neighbouring replication forks may replicate a licensed site passively, and unused licensed origins can provide reserve initiation capacity under stress.

The two helicases are distinct molecular solutions. In the conventional comparison, bacterial DnaB translocates on the lagging strand template, whereas the CMG helicase travels on the leading strand template. Their associated proteins also differ. E. coli uses DNA polymerase III with the beta sliding clamp, a clamp loader, DnaG primase and single-stranded DNA-binding protein. In conventional nuclear eukaryotic replication, DNA polymerase alpha-primase begins synthesis, DNA polymerase epsilon primarily extends the leading strand and DNA polymerase delta primarily extends the lagging strand, supported by PCNA, RFC and replication protein A. These are predominant assignments in the standard system, not an assertion that polymerases can never exchange roles during initiation, repair or stress.

Both systems must repeatedly make and mature Okazaki fragments. In E. coli, DnaG supplies an RNA primer, and DNA polymerase I participates in primer removal and gap filling before DNA ligase seals the backbone. Nuclear eukaryotic initiation uses a short RNA segment followed by DNA made by DNA polymerase alpha-primase. Subsequent strand-displacement synthesis, FEN1 and other processing activities remove primer-containing material, and DNA ligase completes joining. Eukaryotic fragments are generally shorter and their formation is integrated with nucleosome assembly; bacterial and eukaryotic lagging strand maturation should not be reduced to identical protein names with different labels.

A shared replication fork architecture does not imply a perfectly rigid, synchronised machine. single-molecule fluorescence microscopy of reconstituted E. coli replication found that leading- and lagging strand polymerases could pause and change rates independently, while DNA helicase behaviour allowed recoupling. This shows why similar average synthesis rates do not prove lockstep molecular progression.^[ref] Omission controls establish which reaction requires a component, but a purified short-template assay cannot reproduce every obstacle of a living chromosome.

Chromosome context creates further differences. Nuclear DNA is packaged into chromatin, requiring nucleosome disassembly and reassembly and coordination with replication-associated inheritance of chromatin states. Multiple linear chromosomes also create an end-replication problem, commonly addressed by telomerase and specialised telomere maintenance. Bacterial circular chromosomes avoid that particular end problem but still require resolution of DNA supercoiling, DNA catenanes and chromosome dimers. DNA topoisomerases manage topology in both groups. Converging replication forks terminate replication in both; the Tus-Ter system is a specific feature of certain bacteria, including E. coli, rather than a universal bacterial termination mechanism.

Finally, replication is embedded in different cellular schedules. Bacterial synthesis shares the cellular compartment with transcription and must manage collisions with it; nuclear eukaryotic replication also encounters transcription and other obstacles, despite the separation of nuclear transcription from cytoplasmic translation. ATR–Chk1 signalling in many eukaryotes couples replication stress to origin use and cell-cycle progression. Bacteria use their own damage and fork-recovery programmes, including the SOS response. Neither system is simply unregulated.

Archaea should not be grouped indiscriminately with bacteria in this comparison: their lack of a cell nucleus does not make their replication machinery bacterial, and several core components have closer relationships to the eukaryotic machinery. Comparative experiments should therefore ask separately about initiation, elongation, fidelity, chromatin handling and completion. Measure newly synthesised products as well as protein recruitment, verify that an apparent initiation defect is not degradation of the template, and distinguish a replication fork's instantaneous speed from whole-genome completion time. The deepest difference is how distinct molecular machines are organised around chromosome architecture and cell-cycle control; the underlying templated chemistry and the need to preserve complete genomes are shared.

Recurrent drivers reflect repeated selection of accessible changes in shared cellular control systems, filtered by biological tissue context and by how mutations arise. The same individual mutation, different alterations of one gene, and changes in different components of one pathway are three distinct kinds of recurrence. They should be separated before proposing an explanation.

All proliferating human biological cells must regulate growth, survival, resource use and inheritance of their genomes. Disabling a restraint or making a growth-promoting signal constitutive can therefore confer an advantage in more than one biological tissue. Activating KRAS or BRAF can increase RAS-MAPK signalling; activating PIK3CA can increase PI3K-AKT signalling; disruption of TP53 or the RB pathway can weaken responses that normally restrain proliferation. A relatively limited set of regulatory bottlenecks is reused across many differentiated biological cell types. Pan-cancer analysis consequently finds repeated alteration of canonical growth and survival pathways, with frequencies and combinations differing across tumour lineages.^[ref]

positive selection amplifies advantageous clones after the initiating change occurs. A driver mutation raises reproductive success in a particular cellular environment; a passenger mutation can accompany the expanding clone without causing that advantage. Independent tumours can therefore converge on similar solutions even when their other mutations differ. The relevant advantage can be escape from growth restraint, suppression of apoptosis, tolerance of stress or survival after therapy, rather than a simple increase in division rate. A driver at one stage need not be advantageous in every later environment.

Functional constraints help explain recurrence of exact positions. An oncogene often needs an altered protein that retains a useful structure while escaping regulation. Certain KRAS substitutions impair normal switching toward the inactive state; BRAF V600E promotes abnormal kinase activity; particular PIK3CA substitutions activate signalling. Many other changes in the same proteins would merely damage them and provide no comparable benefit. By contrast, a tumour suppressor gene may be disabled by many different nonsense, frameshift, splice-site or deletion events. Consequently, clustered activating hotspots and dispersed inactivating changes can produce different mutation patterns even when both genes are recurrently selected. Some TP53 missense alleles also have dominant-negative or additional context-dependent effects, so not every tumour-suppressor lesion fits an identical two-hit mechanism.

Recurrence is nevertheless generated by mutation supply as well as genotype fitness. Local nucleotide sequence, methylated CpG sites, exposure-related damage, DNA repair and replication-associated processes make some changes more likely than others. A hotspot can therefore recur partly because it is easy to generate. Large genes, late-replicating regions and variable background mutation burdens can yield apparently recurrent passengers if the null model assumes uniform mutability. Analyses allowing for such heterogeneity substantially change which genes are identified as unusually mutated.^[ref]

A conceptual decomposition is useful: the number of observed successful clones carrying an alteration depends on the number of opportunities for it to arise, its context-dependent chance of establishing an expanding lineage, and the chance of detecting that lineage. Thus counting cases with a mutation does not isolate its selective advantage. Gene-level recurrence tests should control mutation opportunity and sequence context; dN/dS analyses compare observed nonsynonymous changes with a suitably calibrated expectation from synonymous changes. Applied to somatic evolution, such approaches provide evidence for selection beyond raw mutation counts.^[ref] The assumptions still require scrutiny: sequencing errors, biased ascertainment and an incorrect background model can mimic enrichment.

Tissue context explains why recurrence is broad but not universal. A particular cell of origin expresses a particular set of receptors, lineage regulators and feedback circuits. The same driver mutation can cooperate with one background, be redundant in another, and cause intolerable stress in a third. Epistasis and mutation order alter its effect. Apparent mutual exclusivity can be consistent with alternative routes to the same pathway output, but it can also result from tumour-subtype structure or limited statistical power; it does not by itself prove that a double mutant is lethal. Similarly, co-occurrence can suggest cooperation without establishing a direct biochemical interaction.

The consequences of a shared lesion can also differ after treatment. An experimental screen in BRAF V600E colorectal-cancer biological cells identified epidermal growth factor receptor feedback as an explanation for weak response to BRAF inhibition compared with the response seen in melanoma. Interfering with the feedback route improved pathway suppression in the tested models. This illustrates that the same driver is embedded in different circuits; recurrence across biological tissues does not imply identical drug sensitivity.^[ref] This is a mechanistic historical example, not a claim that the treatment landscape remains as it was in 2012.

Functional validation should recreate the candidate alteration at its endogenous locus in several relevant cellular backgrounds, compare it with matched wild-type and synonymous controls, and test growth under competitive conditions. Repairing the allele or restoring the affected restraint provides a complementary loss-of-advantage test. Use physiological expression: massive overexpression can make a normally weak effect appear transforming. Measure pathway output, survival and tumour formation separately, and test cooperation with plausible partner lesions. A dependency in an established tumour demonstrates a maintenance requirement, which need not be identical to the alteration's original role in initiation.

The explanation is convergent somatic evolution acting on shared biological machinery, with mutation accessibility, functional constraints and lineage-specific interactions determining which solutions recur. Genomic recurrence identifies candidates; calibrated statistics and controlled experiments establish which recurrent changes are causal and under what conditions.

Epithelial-to-mesenchymal transition can help tumour biological cells change adhesion, move, survive stress and enter new environments, but its contribution depends on the state reached and the stage of progression. Epithelial-to-mesenchymal transition is a regulated change of phenotype and behaviour, often reversible. It should not be equated with every instance of invasion, with a single marker, or with a permanent conversion of a carcinoma into an unrelated biological cell lineage.

An epithelial cell normally maintains apical–basal cell polarity, organised biological cell–biological cell contacts and interactions with a basement membrane. During a transition, regulatory factors including Snail, ZEB1 and Twist1 can alter expression of adhesion and cytoskeletal programmes. Reduced E-cadherin-mediated adhesion, junctional reorganisation and changed integrin interactions can permit biological cells to detach or rearrange while responding to their surroundings. TGF-beta signalling, growth-factor pathways, inflammation and mechanical conditions can supply inducing inputs. Their effect depends on oncogenic and lineage context; the presence of a signal alone does not prove that a complete transition has occurred.

The clearest immediate advantage can be local dissemination. Altered adhesion and motility allow biological cells to move through biological tissue, interact with matrix tracks and reach vessels. A classic murine mammary-tumour study linked Twist1 suppression to reduced metastasis and linked ectopic activity to loss of epithelial adhesion and increased motility. Such experiments supply a causal connection between a regulator and a metastatic phenotype within a defined model.^[ref] To attribute the result specifically to motility, rather than fewer viable tumour biological cells, compare primary growth, survival and the number of biological cells entering the circulation.

Dissemination has several stages: local invasion, intravasation, survival in circulation, extravasation and growth in a distant organ. A transition that helps the first stage need not help the last. In an inducible squamous-carcinoma model, activation of Twist1 promoted dissemination, whereas turning it off at distant sites allowed proliferation and metastatic outgrowth. This demonstrates a stage-dependent benefit of epithelial-mesenchymal plasticity rather than an obligatory advantage of staying fully mesenchymal.^[ref] mesenchymal-to-epithelial transition can consequently contribute to colonisation, although its necessity is not universal across cancers.

Intermediate states are important. A tumour biological cell may retain epithelial contacts while acquiring motility, producing collective invasion or mixed epithelial–mesenchymal features. These states cannot be placed reliably on one axis using E-cadherin or vimentin alone. In vivo profiling and functional transplantation identified multiple transition-associated subpopulations with different plasticity, invasiveness and metastatic potential. Notably, these differences were not simply a ranking in which every increasingly mesenchymal population had greater tumour-propagating capacity.^[ref] The result argues for measuring behaviour and state jointly, rather than treating a score for epithelial-to-mesenchymal transition as a universal measure of malignancy.

Another contribution is treatment persistence. Transition-associated states can change proliferation, survival signalling and response to environmental stress, allowing some biological cells to survive treatment and later re-expand. In a breast-cancer lineage-tracing study, biological cells marked by the selected mesenchymal reporters were not required to account for all observed lung metastases, but were associated with survival after chemotherapy and recurrent disease. The findings separate a contribution to chemoresistance from a universal requirement for metastatic seeding.^[ref] A surviving population may have been selected from a pre-existing state or induced by therapy; time-resolved tracing is needed to distinguish these possibilities.

Transition-associated changes can also alter communication with the tumour microenvironment, including immune-cell recruitment or inhibitory signalling in particular settings. Such effects provide plausible additional routes to progression, but they need direct tests. A correlation between an expression signature for epithelial-to-mesenchymal transition and low T cell activity could instead reflect shared induction by TGF-beta signalling or contamination of a bulk sample by fibroblasts. Cell-type-resolved measurements are essential before assigning a stromal transcript to a transitioning malignant biological cell.

Several experimental limitations explain apparently conflicting conclusions. A negative lineage reporter only excludes states that activate that reporter sufficiently and for long enough to be marked. Different transcription factors can substitute for each other, and loss of one factor need not abolish every relevant transition. Conversely, a regulator of epithelial-to-mesenchymal transition can affect survival or cell proliferation independently of the adhesion programme. Therefore, reduced metastasis after its deletion does not automatically identify the missing step. Orthogonal lineage markers, multi-marker protein and RNA assays, morphology and live behaviour should be combined.

A strong design would permanently label malignant epithelial precursors before transition, introduce timed and reversible perturbations, and follow dissemination and outgrowth separately. Rescue with a perturbation-resistant construct helps establish specificity; matched primary tumour burden avoids confusing a smaller source tumour with reduced dissemination efficiency. Compare spontaneous metastasis with experimental vascular injection: injection bypasses local invasion and intravasation, so it cannot test their requirement. Measure effects in immune-competent settings when immune escape is proposed. Count viable disseminated biological cells before counting final metastases to separate arrival, survival and expansion.

These distinctions also complicate therapeutic inference. Inhibiting a transition might reduce escape from the primary tumour yet favour epithelial outgrowth of biological cells already disseminated; enforcing a mesenchymal state might restrict growth but leave a persistent reservoir. Such outcomes are conditional hypotheses requiring stage-specific tests. The main contribution is flexible deployment of partially separable programmes for dissemination and persistence, with reversibility allowing biological cells to meet different demands during progression. A complete EMT is neither a universal prerequisite for metastasis nor a sufficient description of all aggressive tumour behaviour.

Solid-tumour immunotherapy must overcome a chain of barriers: identify suitable targets, generate effective immune biological cells, deliver them into every relevant lesion, sustain their function and prevent escape without damaging normal biological tissue. Failure at any one step can limit treatment. immune checkpoint blockade, adoptive T-cell therapy and cancer vaccines address different parts of this chain and therefore face overlapping but non-identical challenges.

Successful treatment is possible, so the problem is not a universal inability of immunity to affect solid tumours. For example, a randomised trial in advanced melanoma found longer progression-free survival with expanded tumour-infiltrating lymphocytes than with ipilimumab. The regimen also included preparative lymphodepletion and subsequent interleukin-2, so benefit and toxicity belong to the treatment package rather than the transferred biological cells alone.^[ref] A result in a selected melanoma population cannot simply be transferred to every solid-tumour lineage.

The first challenge is target quality. Many tumour-associated antigens are also present in essential normal biological tissues, whereas truly tumour-specific neoantigens can vary between patients and subclones. T-cell receptors recognise peptides presented by compatible HLA molecules, requiring appropriate processing and presentation. A mutation detected in DNA does not guarantee expression, processing or presentation of an immunogenic peptide. chimeric antigen receptors can recognise a cell-surface target without peptide–HLA presentation, but conventional designs cannot directly access most intracellular proteins. Thus broader target access, tumour coverage and specificity cannot all be assumed from the same targeting strategy.

Even a promising target may be heterogeneous. Cells expressing little antigen can escape a single-target therapy, and different metastases may present different targets or immune environments. Targeting several antigens could reduce escape but can also increase the normal-tissue recognition problem. Multi-region sampling and single-cell measurements improve coverage estimates; one positive biopsy is not proof that all clonogenic tumour biological cells are targetable. A relevant experiment tests killing over a measured range of target densities, including normal biological cells, rather than only a high-expression laboratory line.

Immune activation and entry are separate obstacles. dendritic cells must acquire and present antigen with appropriate activating signals, and responsive T cells must expand and reach the tumour. Abnormal vessels, inadequate chemokine matching and dense or reorganised extracellular matrix can prevent effective entry. A tumour may contain many lymphocytes restricted to the surrounding stroma, with few contacting malignant biological cells. Studies linking a stromal TGF-beta signalling programme to poor response also showed in mouse models that combined pathway and PD-L1 blockade improved intratumoural access and antitumour activity. The causal combination experiment strengthens an inference that human expression correlations alone could not establish.^[ref]

Once inside, immune biological cells face hypoxia, nutrient competition, inhibitory metabolites and suppressive signals from regulatory T cells, tumour-associated macrophages and other stromal populations. Persistent antigen stimulation can establish T-cell exhaustion, with impaired function and a regulatory state that is not always reversed by blocking one inhibitory receptor. PD-1 or CTLA-4 blockade can release important restraints, but cannot reliably restore missing antigen presentation, compensate for absent tumour-reactive clones or abolish every suppressive pathway. Hence a high density of PD-L1 or a large tumour mutational burden can be informative without being a deterministic response predictor.

Tumours also evolve under therapy. Paired pretreatment and relapse samples from a small melanoma series identified acquired defects involving JAK1, JAK2 or beta-2-microglobulin. These connected resistance with impaired interferon-gamma signalling or MHC class I presentation, and functional assays helped interpret the genetic findings. They provide concrete routes by which a previously responsive tumour can escape; a selected four-patient series cannot estimate how often each mechanism explains resistance generally.^[ref] Some escape routes are shared across therapies; others depend on whether recognition uses a peptide–HLA complex or a directly bound surface antigen.

Safety constrains how strongly these barriers can be attacked. immune checkpoint blockade can produce immune-related adverse events in normal organs, while transferred immune biological cells can produce severe inflammatory responses or recognise normal biological tissues bearing the target. An early ERBB2-directed chimeric antigen receptor study reported fatal toxicity; recognition of low-level target in lung epithelium was the authors' proposed explanation, rather than a definitively isolated causal mechanism. It demonstrates why high tumour expression and selective killing in a simple culture assay are insufficient safety evidence.^[ref] Candidate safeguards include restricted receptor activation, controllable persistence and elimination switches, but each trades activity or durability against risk and requires direct validation.

There are practical challenges as well. Autologous biological cell therapy requires accessible biological tissue or biological cells, reproducible manufacture and expansion without losing effective function. A patient may deteriorate before the product is ready. Conditioning and supportive regimens add burdens; local delivery may improve access to one site while missing distant disease. Vaccines face time needed for priming and the possibility that newly activated biological cells still cannot enter or function within the tumour. Combining therapies is mechanistically attractive but can increase toxicity, cost and uncertainty about which component supplies benefit.

Evaluation must therefore match the proposed mechanism. Test antigen recognition with antigen-negative and normal-tissue controls, measure trafficking and spatial contact separately from killing, and monitor immune-cell persistence and function over time. Paired and multi-region biopsies can distinguish absent entry from failed recognition or evolved escape. Clinical trials need appropriate comparators, durable disease-control endpoints and toxicity reporting, not response rate alone. The central challenge is to make recognition, access and sustained function coincide across a heterogeneous evolving tumour while preserving normal biological tissue; no single biomarker or immune intervention guarantees all three.